Key Takeaways:
The settlement resolves FTC litigation over PBM rebate practices and requires CVS to include TrumpRx purchases in health plan deductibles, a shift that could save consumers billions.
CVS Health's Caremark agreed to a global settlement with the Federal Trade Commission on Tuesday that curbs the pharmacy benefit manager's use of drug rebates and requires it to count patient purchases through the TrumpRx program toward health plan deductibles, a move expected to deliver billions of dollars in savings to American consumers.
"The FTC under President Trump won't stand for anticompetitive behavior that drives up prices for American consumers," FTC Chairman Andrew Ferguson said in a statement announcing the deal.
The settlement resolves all outstanding FTC litigation and investigations involving rebate practices, pharmacy network contracting, and vertical integration at CVS Health, which operates both the Caremark PBM and an affiliated pharmacy chain. CVS Caremark will offer clients the option to opt out of rebate payment models — arrangements in which drugmakers pay rebates to PBMs that may or may not be passed to plan sponsors or patients. The company will also move away from rebate guarantees and spread pricing, simplify its pricing structures, and expand reporting on drug pricing and member payments.
CVS Caremark negotiated nearly $80 billion in savings for clients and their members on prescription drugs last year alone, according to the company. It delivered roughly $900 million in point-of-sale rebate savings to 25 million Americans in 2025. Through greater adoption of point-of-sale rebate passthrough and continued innovation, the company expects to help clients generate about $450 million in annual savings over each of the next 10 years.
The TrumpRx component is among the most consequential provisions. President Donald Trump launched TrumpRx.gov in February, offering hundreds of generic and branded drugs at a discount, with a focus on popular weight-loss medications from Eli Lilly and Novo Nordisk. The website has operated outside insurance networks, limiting its value for consumers who must meet deductibles before their coverage kicks in. Under the settlement, CVS will count TrumpRx purchases toward member deductibles and out-of-pocket maximums where permitted by law, once regulations facilitating the program are in place.
The agreement mirrors one Cigna reached with the FTC earlier this year, signaling a broader regulatory push to restructure how PBMs operate. The three largest PBMs — CVS Caremark, Cigna's Express Scripts, and UnitedHealth's OptumRx — control roughly 80 percent of the U.S. prescription drug market, according to industry data. Any structural changes imposed on one are likely to ripple across the sector.
CVS also agreed to cap insulin costs at $25 per month for members through a new affordability offering, delink manufacturer compensation from list prices, and transition to acquisition-based reimbursement for independent retail pharmacies. The company will disclose broker and consultant compensation as part of expanded transparency measures.
For CVS Health, the settlement removes a significant regulatory overhang that has weighed on the stock as investors weighed the risk of forced structural changes to its PBM model. The company's health services segment, anchored by Caremark, generated more than $170 billion in revenue in 2025, accounting for the bulk of CVS Health's top line. Any disruption to that model could have material implications for earnings.
The FTC's enforcement push against PBMs is unlikely to end here. With Cigna and now CVS under consent agreements, attention will turn to UnitedHealth's OptumRx, which has faced similar scrutiny over rebate practices and vertical integration. The agency has signaled it views the PBM business model — in which the same company negotiates drug prices, processes claims, and operates pharmacies — as inherently prone to conflicts that inflate costs.
This article is for informational purposes only and does not constitute investment advice.
